|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.25/0.22
|
企業價值
3.25B
|
資產負債 |
每股賬面淨值
4.33
|
現金流量 |
現金流量率
0.07
|
損益表 |
收益
838.00M
|
每股收益
1.33
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/11/10 19:54 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |